Advertisement
AMGN vs NVS
Which Stock Would AI Choose? Amgen (AMGN) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Both AMGN and NVS operate in the biopharmaceutical sector with significant exposure to oncology and specialty therapeutics, creating overlapping yet differentiated market positions.
- Recent market activity has shown AMGN demonstrating more consistent upward momentum amid pipeline updates, while NVS has exhibited steadier but more moderate price behavior tied to broader healthcare sector trends.
- Growth drivers for AMGN center on biosimilar competition management and late-stage assets, whereas NVS benefits from diversified geographic revenue and ongoing portfolio optimization through divestitures.
- Risk factors include regulatory scrutiny and patent expirations for both, with AMGN facing higher volatility from product concentration and NVS navigating currency and global pricing pressures.
- Sector sentiment remains constructive for innovative drug developers, supporting relative outperformance potential versus broader indices during periods of market rotation into healthcare.
- Comparative positioning highlights trade-offs between AMGN’s focused innovation profile and NVS’s scale and stability advantages.
Introduction
This comparison examines AMGN (Amgen Inc.) and NVS (Novartis AG), two established biopharmaceutical companies whose stocks appeal to investors seeking healthcare sector exposure. The analysis is relevant for traders monitoring relative performance within the pharmaceuticals and biotechnology industry, as well as longer-term investors evaluating portfolio diversification across growth-oriented and diversified drug developers. By reviewing recent market behavior, business fundamentals, and observable catalysts, the article provides objective context for assessing how these equities have responded to current economic and sector-specific conditions.
AMGN Overview and Recent Performance
Amgen Inc. is a leading biotechnology company focused on developing therapies in oncology, hematology, nephrology, and inflammation. Its portfolio includes established products such as Enbrel and newer assets in cardiovascular and oncology areas. In recent weeks, AMGN stock has reflected positive sentiment driven by pipeline progress and earnings resilience amid broader market fluctuations. Performance has been supported by management commentary on biosimilar strategies and clinical milestones, contributing to relatively stable upward price movement compared with sector peers. Market participants have noted the company’s ability to navigate competitive pressures in key therapeutic categories, sustaining investor interest during recent healthcare rotations.
NVS Overview and Recent Performance
Novartis AG is a global pharmaceutical company with a broad portfolio spanning oncology, cardiology, neuroscience, and ophthalmology, complemented by a significant presence in generics and emerging markets. In recent market activity, NVS has displayed measured price behavior aligned with defensive healthcare characteristics. Developments such as portfolio streamlining and continued investment in high-value assets have helped maintain steady sentiment. The stock’s performance has been influenced by global revenue diversification and cost-management initiatives, resulting in lower volatility relative to more concentrated biotechnology names during the same period.
Trending AI Robots
Tickeron offers a curated selection of AI trading bots through its Trending AI Robots page. The platform hosts hundreds of AI Trading Bots capable of trading thousands of different tickers, yet only those demonstrating the strongest alignment with prevailing market conditions are featured in this trending section. Available bots span a wide range of performance statistics, with historical win rates commonly falling between 55% and 75% depending on strategy and timeframe, alongside varying drawdown profiles and trade frequencies. Each bot employs distinct trading styles, time horizons, and ticker sets, enabling users to explore options suited to different risk tolerances and market views. For further details on current trending options, visit the Trending AI Robots page.
Head-to-Head Comparison
AMGN operates with a more concentrated focus on innovative biologics and specialty medicines, generating growth primarily through pipeline advancement and lifecycle management of key assets. In contrast, NVS maintains broader diversification across therapeutic areas and geographies, supported by a larger revenue base that provides greater stability. Recent momentum has favored AMGN in periods of positive clinical news flow, while NVS has shown resilience through consistent dividend payouts and operational discipline. Risk profiles differ notably: AMGN carries elevated exposure to single-product concentration and regulatory outcomes, whereas NVS contends with foreign exchange fluctuations and pricing negotiations across multiple markets. Sector sentiment for both remains constructive given ongoing demand for innovative treatments, yet the trade-off lies in AMGN’s higher-beta growth potential versus NVS’s defensive qualities.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and relative positioning within the healthcare sector, Tickeron’s AI would currently assign a modest probabilistic preference to AMGN over NVS. This assessment reflects AMGN’s demonstrated momentum in recent market activity alongside pipeline visibility, though outcomes remain contingent on continued execution and broader market conditions. NVS continues to represent a lower-volatility alternative with established scale advantages.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and NVS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green whileNVS’s FA Score has 4 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 6 bullish TA indicator(s).
- AMGN’s TA Score: 4 bullish, 5 bearish.
- NVS’s TA Score: 6 bullish, 3 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +0.80% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.78%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +5.54%.
Reported Earning Dates
AMGN is expected to report earnings on Aug 04, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.78% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | NVS | AMGN / NVS | |
| Capitalization | 197B | 290B | 68% |
| EBITDA | 16.7B | 22.4B | 75% |
| Gain YTD | 13.536 | 14.896 | 91% |
| P/E Ratio | 25.34 | 21.43 | 118% |
| Revenue | 37.2B | 56.6B | 66% |
| Total Cash | 12B | 6.98B | 172% |
| Total Debt | 57.3B | 47B | 122% |
AMGN | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 19 | 6 | |
SMR RATING 1..100 | 12 | 28 | |
PRICE GROWTH RATING 1..100 | 27 | 47 | |
P/E GROWTH RATING 1..100 | 59 | 25 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (9) in the Biotechnology industry is in the same range as NVS (10) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as AMGN (19) in the Biotechnology industry. This means that NVS’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as NVS (28) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.
AMGN's Price Growth Rating (27) in the Biotechnology industry is in the same range as NVS (47) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (59) in the Biotechnology industry. This means that NVS’s stock grew somewhat faster than AMGN’s over the last 12 months.
| AMGN | NVS | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 55% | N/A |
| Stochastic ODDS (%) | 4 days ago 54% | 4 days ago 57% |
| Momentum ODDS (%) | 4 days ago 52% | 4 days ago 50% |
| MACD ODDS (%) | 4 days ago 51% | 4 days ago 37% |
| TrendWeek ODDS (%) | 4 days ago 61% | 4 days ago 43% |
| TrendMonth ODDS (%) | 4 days ago 58% | 4 days ago 50% |
| Advances ODDS (%) | 5 days ago 59% | 4 days ago 52% |
| Declines ODDS (%) | 7 days ago 51% | 7 days ago 46% |
| BollingerBands ODDS (%) | 4 days ago 52% | 4 days ago 59% |
| Aroon ODDS (%) | 4 days ago 53% | 4 days ago 48% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.